Department of General Practice, University Medical Centre Groningen, University of Groningen, Ant, Deusinglaan 1, Groningen, 9713 AV, The Netherlands.
BMC Fam Pract. 2012 Nov 21;13:111. doi: 10.1186/1471-2296-13-111.
In an attempt to control chronic benzodiazepine use and its costs in the Netherlands, health care insurance reimbursement of this medication was stopped on January 1st 2009. This study investigates whether benzodiazepine prescriptions issued by general practitioners changed during the first two years following implementation of this regulation.
Registry study based on data from all benzodiazepine users derived from the Registration Network Groningen. This general practice-based research network collects longitudinal data on the primary care administered to about 30,000 patients. Based on the number of quarterly accumulated prescription days, a comparison was made of benzodiazepine prescriptions issued between 2007/2008 and 2009/2010. Also investigated was which type of user (i.e. short-term or long-term) showed the most change.
Information on benzodiazepine prescriptions among 5,200 patients from 16 consecutive trimesters between 2007 and 2010 was available for analysis. A significant reduction in prescription days was observed between 2007/2008 and 2009/2010. Overall, an estimated 1.73 (CI:-1.94 to -1.53; p<0.001) days were less prescribed per trimester after the termination of reimbursement. In particular, short-term users experienced a reduction in prescription days in 2009 and 2010. The number of long-term users decreased by 2.3%, while the number of individuals that did not use increased by 4.2%.
A total reduction of almost 14 prescription days was observed over eight trimesters after implementation of the regulation to terminate the reimbursement of benzodiazepines. Short-term users were mainly responsible for this reduction in prescription days in 2009 and 2010. Although long-term users did not alter their benzodiazepine use in 2009 and 2010, the number of long-term users decreased slightly.
为了控制荷兰慢性苯二氮䓬类药物的使用及其费用，自 2009 年 1 月 1 日起，医疗保险停止报销此类药物。本研究旨在调查该规定实施后的头两年，普通医生开具的苯二氮䓬类药物处方是否发生变化。
本研究基于格罗宁根注册网络（Registration Network Groningen）所有苯二氮䓬类药物使用者的数据进行了一项注册研究。该基层医疗研究网络收集了约 30000 名患者的初级保健纵向数据。根据每季度累计的处方天数，比较了 2007/2008 年和 2009/2010 年开具的苯二氮䓬类药物处方。同时还研究了哪种类型的使用者（即短期或长期）变化最大。
在 2007 年至 2010 年的 16 个连续季度中，有 5200 名患者的苯二氮䓬类药物处方信息可用于分析。与 2007/2008 年相比，2009/2010 年的处方天数显著减少。总体而言，每个季度的处方量估计减少了 1.73 天（95%CI：-1.94 至-1.53；p<0.001），这一结果在停止报销后 8 个季度内一直存在。特别是，短期使用者在 2009 年和 2010 年减少了处方天数。长期使用者的数量减少了 2.3%，而未使用者的数量增加了 4.2%。
在停止报销苯二氮䓬类药物的规定实施后的八个季度内，处方量总共减少了近 14 天。短期使用者是 2009 年和 2010 年处方量减少的主要原因。尽管长期使用者在 2009 年和 2010 年没有改变他们的苯二氮䓬类药物使用情况，但长期使用者的数量略有减少。
